GTBP | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 10%

Performance

5 Days

13.88%

1 Month

5.09%

3 Months

53.11%

6 Months

5.26%

1 Year

-58.01%

2 Year

193.58%

Key data

Stock price

$3.06

P/E Ratio

0.00

DAY RANGE

$2.94 - $3.10

EPS

$0.00

52 WEEK RANGE

$0.27 - $10.50

52 WEEK CHANGE

-$58.33

MARKET CAP

4.804 M

YIELD

N/A

SHARES OUTSTANDING

2.234 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,108,212

AVERAGE 30 VOLUME

$1,105,131

Company detail

CEO: Michael Breen
Region: US
Website: gtbiopharma.com
Employees: 8
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate, is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company was formerly known as OXIS International, Inc

GTBP - GT Biopharma, Inc.